pharmaceuticals

Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares made a handy gain early Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech ...
Read Full Story »

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Are Loxo Shareholders Getting Enough in the Buyout?

Loxo Oncology Inc. (NASDAQ: LOXO) shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly and Co. (NYSE: LLY). The ...
Read Full Story »

Major Biopharma Catalysts Coming in the First Quarter of 2019

Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to ...
Read Full Story »

Teva and Amgen Settle Over Kidney Disease Patent Infringement

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced on Thursday that it has settled with Amgen Inc. (NASDAQ: AMGN) for its treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney ...
Read Full Story »

Bristol-Myers, Celgene to Tie a $74 Billion Knot

There's nothing like spending $74 billion on an acquisition to get shareholders' attention. That's what Bristol-Myers Squibb Co. (NYSE: BMY) found out Thursday morning following the announcement of a definitive ...
Read Full Story »

Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan

Merck & Co. Inc. (NYSE: MRK) has announced that its blockbuster drug Keytruda received a series of approvals in Japan. The firm said that its anti-PD-1 therapy has simultaneously received ...
Read Full Story »

Is Spectrum Pharma’s FDA Update Good News for Breast Cancer Patients?

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares dipped on Thursday after the firm announced a key update from the U.S. Food and Drug Administration (FDA). Specifically, the firm announced that it ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Meet Thursday’s Biggest Biotech Movers

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff. Although the sector is feeling the pinch from the ...
Read Full Story »

Meet Pfizer and GlaxoSmithKline’s New Joint Venture

GlaxoSmithKline PLC (NYSE: GSK) shares bounced higher on Wednesday after the company announced a new joint venture with Pfizer Inc. (NYSE: PFE). These two firms will create a premier global ...
Read Full Story »

Eli Lilly Scores Solid Results in Psoriatic Arthritis Study

Eli Lilly and Co. (NYSE: LLY) has announced positive results from its late-stage active psoriatic arthritis (PsA) study. This trial is the first completed large head-to-head superiority study in active ...
Read Full Story »

Johnson & Johnson Under Fire After Claims of Asbestos in Baby Powder

Reuters reported on Friday that Johnson & Johnson (NYSE: JNJ) knew for decades that its baby powder sometimes contained the known carcinogen asbestos. According to the report, the pharmaceutical and health ...
Read Full Story »

Eli Lilly Receives Crucial FDA Update on Lupus Study

The U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to Eli Lilly and Co.'s (NYSE: LLY) baricitinib, which is being studied for the treatment of systemic lupus ...
Read Full Story »

Major Pharma Stocks See a Surge in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »